Septal myectomy for hypertrophic obstructive cardiomyopathy in Friedreich's ataxia.

Septal myectomy for hypertrophic obstructive cardiomyopathy in Friedreich's ataxia. Anderson HN, Burkhart HM, Johnson JN; Cardiol Young. 2015 Feb 17:1-4. [Epub ahead of print] 10.1017/S104795111500013X

Keywords: Friedreich’s ataxia, hypertrophic cardiomyopathy, septal myectomy

This suggests that septal myectomy may be a viable option to relieve symptoms and interrupt progression of heart disease in appropriately selected Friedreich’s ataxia patients.

Very late-onset friedreich ataxia with laryngeal dystonia.

Very late-onset friedreich ataxia with laryngeal dystonia. Rota S. · Marchina E., Todeschini A., Nanetti L., Rinaldi F., Vanotti A., Mariotti C., Padovani A., Filosto MM, Case Rep Neurol 2014;6:287-290 (DOI:10.1159/000370062)

OPEN ACCESS

A novel GAA repeat expansion-based mouse model of Friedreich ataxia.

A novel GAA repeat expansion-based mouse model of Friedreich ataxia. Anjomani Virmouni S, Ezzatizadeh V, Sandi C, Sandi M, Al-Mahdawi S, Chutake Y, Pook MA. Dis Model Mech. 2015 Feb 13. pii: dmm.018952. [Epub ahead of print] doi: 10.1242/dmm.018952

OPEN ACCESS, FULL TEXT PDF

Navigating through orphan medicinal product regulations in EU and US – Similarities and differences

Navigating through orphan medicinal product regulations in EU and US – Similarities and differences. Jyoti Tiwari, Regulatory Toxicology and Pharmacology, Volume 71, Issue 1, February 2015, Pages 63-67, ISSN 0273-2300, http://dx.doi.org/10.1016/j.yrtph.2014.11.006.

Full text, PDF

Ferredoxin, in conjunction with NADPH and Ferredoxin-NADP reductase, transfers electrons to the complex IscS/IscU to promote iron-sulfur cluster assembly

Ferredoxin, in conjunction with NADPH and Ferredoxin-NADP reductase, transfers electrons to the complex IscS/IscU to promote iron-sulfur cluster assembly. Robert Yan, Salvatore Adinolfi, Annalisa Pastore, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, Available online 14 February 2015, ISSN 1570-9639, http://dx.doi.org/10.1016/j.bbapap.2015.02.002.

Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE® in the Treatment of Friedreich's Ataxia

Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE® in the Treatment of Friedreich's Ataxia
. Marketwired, February 13, 2015

SOURCE: Horizon Pharma plc

Phase 3 Study Expected to Begin in Q2 2015

PIPs in neurological diseases

PIPs in neurological diseases. M.G. Waugh, Biochim. Biophys. Acta (2015), http://dx.doi.org/10.1016/j.bbalip.2015.02.002

There has been an interesting development recently concerning the possible involvement of PIP5K1B in Friedreich's ataxia.

Thérapie génique : 3 millions d’euros pour AAVLife

Thérapie génique : 3 millions d’euros pour AAVLife. Bpifrance 12 février 2015


Gene therapy for FA is blooming, yesterday knew the good news of the major strategic collaboration between Sanofi-Genzyme and Voyager Therapeutics, today it has known the news of a new economic aportacion to AAVLIFE project, which develops a gene therapy with AAV vectors for FA, targeted to the heart


Bpifrance investit, via le Fonds Biothérapies innovantes et Maladies rares, 3 millions d’euros dans la société de thérapie génique AAVLife. Une opération va lui permettre de faire progresser la thérapie génique pour le traitement des cardiomyopathies liées à l’ataxie de Friedreich.

Related news:


AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.

AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia

Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders

Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders. (BUSINESS WIRE) February 11, 2015.

Sanofi embarks on an $845M gene therapy R&D odyssey with Voyager


Up to $845 Million Collaboration to Support Development, Expansion and Commercialization of Voyager’s Novel CNS Product Pipeline


Press Release (PDF): Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders.

Long term follow up of cardiomyopathy in Friedreich Ataxia

Long term follow up of cardiomyopathy in Friedreich Ataxia. (25es Journées Européennes de la Société Française de Cardiologie – 14-17 janvier 2015, Paris) Lise Legrand, Françoise Pousset, Sophie Tezenas du Montcel, Marie Lorraine Monin, Alina Tataru, Michel Komajda, Alexandra Durr, Richard Isnard; Archives of Cardiovascular Diseases Supplements, Volume 7, Issue 1, January 2015, Page 27, ISSN 1878-6480, http://dx.doi.org/10.1016/S1878-6480(15)71565-X.

GAA repeats are the best predictors of survival and cardiac events in FRDA patients, but EF and LV mass are also predictors of long term evolution